Immunotech Biopharm Ltd
HKEX:6978
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (36.8), the stock would be worth HK$-13.08 (548% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -8.2 | HK$2.92 |
0%
|
| Industry Average | 36.8 | HK$-13.08 |
-548%
|
| Country Average | 28.9 | HK$-10.27 |
-452%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Immunotech Biopharm Ltd
HKEX:6978
|
1.8B HKD | -8.2 | -6.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 19.5 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 14 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 14.7 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 21.6 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 14.9 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 41.1 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 13.1 | 30.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.6 |
| Median | 28.9 |
| 70th Percentile | 52.9 |
| Max | 49 021 |
Other Multiples
Immunotech Biopharm Ltd
Glance View
Immunotech Biopharm Ltd. operates as an investment holding company, which through its subsidiaries engages in research and development, manufacturing and commercialization of immune cell products for treatments of cancers in the PRC. The company is headquartered in Beijing, Beijing and currently employs 515 full-time employees. The company went IPO on 2020-07-10. Its main products are EAL, CAR-T cell series and TCR-T cell series products. EAL is a multi-target cellular immunotherapy product. The company also provides cell cryopreservation services. The firm mainly conducts its businesses in the domestic market.
